Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
News Medical on MSN1d
Insilico Medicine announces developmental candidate benchmarks and timelines for novel therapeutics discovered using generative AIInsilico Medicine pulls back the curtain on developmental timelines, highlighting a ~13 month average timeline to reach developmental candidate (DC) nomination across 22 programs. Insilico’s QPCTL ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...
Sentinel & Enterprise on MSN5dOpinion
Editorial: Psychedelics lobby turns to lawmakers’ clinically-based billsPlant-based medicine advocates haven’t given up their efforts to see that therapeutic method take root. Question 4, defeated ...
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
7d
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinic ...
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback